Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

0
Player Avatar EclecticRecluse (77.78) Submitted: 5/5/2011 4:31:17 AM : Outperform Start Price: $95.84 BIIB Score: +38.75

Upward Momentum

Featured Broker Partners


Advertisement